These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 39098922)

  • 1. BCR::ABL1 Proteolysis-targeting chimeras (PROTACs): The new frontier in the treatment of Ph
    Cruz-Rodriguez N; Tang H; Bateman B; Tang W; Deininger M
    Leukemia; 2024 Sep; 38(9):1885-1893. PubMed ID: 39098922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia - a patent review.
    Vicente ATS; Salvador JAR
    Expert Opin Ther Pat; 2023; 33(6):397-420. PubMed ID: 37494069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.
    Burslem GM; Schultz AR; Bondeson DP; Eide CA; Savage Stevens SL; Druker BJ; Crews CM
    Cancer Res; 2019 Sep; 79(18):4744-4753. PubMed ID: 31311809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells.
    Nemethova V; Babiakova P; Teglasova B; Uhelska L; Babelova A; Selc M; Jakic K; Mitrovsky O; Myslivcova D; Zackova M; Poturnayova A; Batorova A; Drgona L; Razga F
    Am J Physiol Cell Physiol; 2024 Jul; 327(1):C184-C192. PubMed ID: 38826137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia.
    Adnan Awad S; Dufva O; Klievink J; Karjalainen E; Ianevski A; Pietarinen P; Kim D; Potdar S; Wolf M; Lotfi K; Aittokallio T; Wennerberg K; Porkka K; Mustjoki S
    Cell Rep Med; 2024 May; 5(5):101521. PubMed ID: 38653245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells.
    Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J
    Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-inducible factor 1α inhibitor induces cell death via suppression of BCR-ABL1 and Met expression in BCR-ABL1 tyrosine kinase inhibitor sensitive and resistant chronic myeloid leukemia cells.
    Tsubaki M; Takeda T; Matsuda T; Kimura A; Tanaka R; Nagayoshi S; Hoshida T; Tanabe K; Nishida S
    BMB Rep; 2023 Feb; 56(2):78-83. PubMed ID: 36195570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
    Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
    Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
    Eiring AM; Page BDG; Kraft IL; Mason CC; Vellore NA; Resetca D; Zabriskie MS; Zhang TY; Khorashad JS; Engar AJ; Reynolds KR; Anderson DJ; Senina A; Pomicter AD; Arpin CC; Ahmad S; Heaton WL; Tantravahi SK; Todic A; Moriggl R; Wilson DJ; Baron R; O'Hare T; Gunning PT; Deininger MW
    Leukemia; 2015 Mar; 29(3):586-597. PubMed ID: 25134459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.
    Patel AB; O'Hare T; Deininger MW
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):589-612. PubMed ID: 28673390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia.
    Wu A; Liu X; Fruhstorfer C; Jiang X
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
    Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
    Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.
    Kockerols C; Valk PJM; Janssen JJWM; Hogenbirk P; Cornelissen JJ; Saussele S; Spiess B; Perusini MA; Kim D; Westerweel PE
    Eur J Haematol; 2024 Nov; 113(5):606-613. PubMed ID: 38994654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
    Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
    Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
    Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
    Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
    Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
    Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
    [No Abstract]   [Full Text] [Related]  

  • 18. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
    Aranda-Tavío H; Recio C; Martín-Acosta P; Guerra-Rodríguez M; Brito-Casillas Y; Blanco R; Junco V; León J; Montero JC; Gandullo-Sánchez L; McNaughton-Smith G; Zapata JM; Pandiella A; Amesty A; Estévez-Braun A; Fernández-Pérez L; Guerra B
    Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Progress of Small Molecule Targeting BCR-ABL in the Treatment of Chronic Myeloid Leukemia.
    Zhang Y; Wu X; Sun X; Yang J; Liu C; Tang G; Lei X; Huang H; Peng J
    Mini Rev Med Chem; 2024; 24(6):642-663. PubMed ID: 37855278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
    Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
    JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.